Johnson & Johnson: Buying the Doctor’s Decision

In the Johnson & Johnson FCPA case announced in April 2011, the company agreed to give up $38,227,826 in profits to settle Securities and Exchange Commission allegations of bribing public doctors in Europe and paying kickbacks for Iraqi supply contracts. The alleged payments reached people who selected surgical implants, awarded hospital contracts, and prescribed medicines. If you work in medical sales, purchasing, or finance, those are decisions you may see long before anyone outside the business sees the payment behind them.

Johnson & Johnson manufactured and sold medical devices, pharmaceuticals, and consumer health care products. In its April 8, 2011 announcement, the Justice Department said the company acknowledged responsibility under its criminal deferred prosecution agreement for improper payments by subsidiaries, employees, and agents to publicly employed health care providers in Greece, Poland, and Romania. The company also acknowledged kickbacks to the former Iraqi government to secure humanitarian-supply contracts under the United Nations Oil for Food Program.

The Securities and Exchange Commission’s civil settlement announcement describes the profit repayment as disgorgement. Its Foreign Corrupt Practices Act case connects the company’s sales to the public decisions allegedly bought with cash, travel, sham contracts, and offshore companies. That connection is what makes this more than a large entry in a list of FCPA settlements: the customer’s decision and the seller’s payment belong in the same story.

Greece and the DePuy Implant Business

The Securities and Exchange Commission alleged that Johnson & Johnson subsidiaries paid public doctors in Greece who selected the company’s surgical implants. The Justice Department’s announcement separately identified DePuy Inc. as the subsidiary charged in a criminal information with conspiracy and Foreign Corrupt Practices Act violations concerning payments to public physicians in Greece.

For an implant supplier, the doctor’s product choice is the commercial prize. Here, the SEC’s allegation joined that choice to a payment from the seller. The medical-device bribery pattern becomes recognizable when the person selecting the product also benefits from money spent to sell it.

That is why the customer’s role matters as much as the payee’s name. A sales employee may know which physician determines the implant used, while a finance employee sees the payment approved for that same physician. We connect those accounts to the public purchasing decision and the business the supplier gained.

Hospital Contracts in Poland, Prescriptions in Romania

In Poland, the commission alleged payments to public doctors and hospital administrators who awarded contracts to Johnson & Johnson. In Romania, it alleged payments to public doctors to prescribe the company’s pharmaceuticals. The agency said the European conduct extended back to at least 1998.

A hospital contract and a prescription give a sales team different ways to measure results. The Polish allegations concern access to the contract award. The Romanian allegations concern the doctor’s choice of medicine. Both put the person responsible for a public health care decision on the receiving end of a supplier’s alleged inducement.

In its 2015 speech, FCPA, Disclosure, and Internal Controls Issues Arising in the Pharmaceutical Industry, the Securities and Exchange Commission’s enforcement director described pharmaceutical representatives’ regular contact with public-hospital doctors, pharmacists, and administrators who decide which products hospitals and pharmacies buy. The speech identified payments for prescriptions as a recurring enforcement pattern. Johnson & Johnson’s Romanian allegations place that pay-to-prescribe mechanism in a specific sales relationship.

We see a public health system relying on a doctor’s judgment while the seller allegedly pays for it. The product is for the hospital. The perk is for the person choosing it.

Cash, Travel, and Contracts With Doctors

The commission’s account of its complaint said doctors and administrators who ordered or prescribed Johnson & Johnson products received cash and inappropriate travel. It alleged that subsidiaries, employees, and agents used slush funds, sham civil contracts with doctors, and offshore companies in the Isle of Man to carry out the bribery. Its enforcement director also said Johnson & Johnson acquired a private company for the purpose of paying bribes. Buying a business to buy the customer. Those allegations explain why a payment’s description can be a poor guide to its purpose.

A contract for supposed services gives the finance department something to process. The important connection is between the promised work, the person receiving the benefit, and the purchase or prescription the sales team wanted.

The pharmaceutical-industry speech adds a useful explanation of the distributor’s role. It describes how a distributor’s margin can supply a cash fund for bribes and how that extra layer can leave improper payments recorded as ordinary expenses. That industry pattern helps explain why we examine both the company’s payment and what the intermediary did with it.

Iraq’s Oil for Food Supply Contracts

The Iraqi strand concerned kickbacks to obtain contracts under the United Nations Oil for Food Program. The Securities and Exchange Commission alleged that Johnson & Johnson subsidiaries paid them to obtain 19 contracts. The Justice Department reported that, under its criminal deferred prosecution agreement, Johnson & Johnson acknowledged kickbacks paid on behalf of subsidiary companies to the former Iraqi government to secure humanitarian-supply business.

Here the purchase being influenced was a supply contract under a humanitarian program. The transaction questions therefore concern the contract, the company supplying the goods, the payment made on its behalf, and the government recipient. A person who knows how the contract was won may explain a connection that the invoice alone leaves out.

What the Sales Team Knows and the Ledger Misses

The useful whistleblower evidence connects the customer’s authority, the company’s payment, and the record used to explain it. In this case, the agencies described public doctors, hospital administrators, subsidiaries, agents, contracts, cash, and travel. Different people inside the business see different parts of that relationship.

Sales and product staff may know who selects the implant, awards the hospital contract, or prescribes the drug. They may also know what business a payment was expected to produce. That knowledge gives meaning to an approval or expense entry that finance sees without the customer conversation.

Finance and distributor employees may know who received the money, the stated service, the supplier’s price, and the margin retained before the product reached the customer. Contracts, invoices, payment approvals, and accounting entries can connect those amounts to the person making the public decision. Audit and compliance staff may know which questions were raised and how management answered them.

In Johnson & Johnson’s case, the commission described internal auditors investigating conduct in more than a dozen countries. The Justice Department said the company’s assistance helped its wider investigation of improper practices in the life-sciences industry. The people examining the company’s own transactions helped investigators see beyond it.

We work with the connection between those accounts. Knowing what the doctor could award, what the salesperson expected, and what finance was told can expose the purpose of a payment far more clearly than its label in the ledger.

The Same Public Customer in Other Healthcare Cases

Novartis Hellas shows how directly a sales team can connect benefits to prescriptions. In its separate 2020 order concerning Novartis, the commission described employees ranking doctors by prescribing preference and volume, then managing inducements according to the expected return. The order quoted an ophthalmology manager’s action plan:

That is a sales bargain stated in the company’s own language. Read beside Johnson & Johnson’s alleged payments to prescribing doctors, it shows why a sales plan can explain the purpose of a benefit more plainly than the document approving its cost.

Fresenius Medical Care supplies the procurement comparison. The Securities and Exchange Commission’s order described the company’s Spanish business giving a public-hospital doctor proposed tender specifications, a scoring method, and proposed scores to win the tender. The doctor used a personal email account to agree to some of the proposals, and the company won the contract. The seller was helping write the terms on which its own bid would be judged.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA examines how employees and managers circumvented controls despite flagged transactions. Its account connects subsidiary payments, false expense descriptions, and accounts consolidated by the parent. The lesson for someone reviewing medical sales is concrete: the label at headquarters can look routine while the local payment buys influence over a public customer’s decision.

Whistleblower Rewards Depend on the Kind of Case

What you know about foreign bribery may fit a whistleblower award program, and we work out which one with you. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. That range concerns false claims on government money, a different kind of case from this foreign-bribery matter.

You Know What the Payment Was Buying

If you saw a doctor’s benefit tied to implant sales, prescriptions, or a public contract, speak to one of our Whistleblower Experts about what the payment was buying. We bring the sales decisions and payment records together with you, engage foreign-bribery whistleblower lawyers who understand medical-device and pharmaceutical cases, and stay beside you to build your strongest foreign-bribery whistleblower case.